Takeda Pharmaceutical Co. Ltd. has presented further long-term results from an ongoing Phase III trial with its dengue vaccine TAK-003, showing continued protection against dengue illness and hospitalization, regardless of previous exposure to the mosquito-borne virus, out to three years following vaccination.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?